Neuroscience and Behavioral Physiology

, Volume 39, Issue 6, pp 587–590 | Cite as

The contribution of serotonin 1A receptors to kappa opioid immunosuppression

  • M. A. Cheido
  • G. V. Idova

Activation of kappa opioid receptors (kappa-OR) with the selective agonist rimorphin (0.1 mg/kg) produced marked suppression of the immune response in CBA mice. This effect was not seen on administration of rimorphin on the background of a reduction in the activity of the serotoninergic (5-HTergic) system resulting from stimulation of presynaptic (8-OH-DPAT, 0.1 mg/kg) or blockade of postsynaptic (WAY-100635, 1.0 mg/kg) 5-HT1A receptors. These data led to the conclusion that 5-HTergic mechanisms involving preand postsynaptic 5-HT1A receptors have a role in kappa-opioid-mediated immunosuppression.


immunosuppression kappa opioid receptors rimorphin 5-HT1A receptors 8-OH-DPAT WAY-100635 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    S. M. Davydova, “Involvement of pre- and postsynaptic 5-HT1A and postsynaptic 5-HT2A serotonin receptors in immunomodulation,” Patogenez, 1, 47–48 (2006).Google Scholar
  2. 2.
    L. V. Devoino and R. Yu. Il’yuchenok, Neurotransmitter systems in Psychoneuromodulation: Dopamine, Serotonin, GABA, Neuropeptides [in Russian], TsÉRIS, Novosibirsk (1993).Google Scholar
  3. 3.
    G. V. Idova and M. A. Cheido, “Stimulation of the immune response on blockade of serotoninergic receptors with ciproheptadine,” Byull. Éksperim. Biol. Med., 4, 440–442 (1987).Google Scholar
  4. 4.
    G. V. Idova, M. A. Cheido, and S. M. Davydova, “Effects of activation and blockade of serotonin 5-HT1A receptors on the immuneresponse in CBA mice,” Éksperim. Klinich. Farmakol., 68, No. 1, 42–44 (2005).Google Scholar
  5. 5.
    G. N. Kryzhanovskii, S. V. Magaeva, S. V. Makarov, and R. I. Sepiashvili, Neuroimmunopathology [in Russian], Research Institute of General Pathology and Pathophysiology Press (2003).Google Scholar
  6. 6.
    N. K. Popova, V. S. Naumenko, and I. Z. Plyusnina, “Involvement of brain 5-HT1A serotonin receptors in the genetic predisposition to aggressive behavior,” Zh. Vyssh. Nerv. Deyat., 56, No. 4, 537–542 (2006).Google Scholar
  7. 7.
    M. A. Cheido and G. V. Idova, “Effects of opioid peptides on immunomodulation processes,” Ros. Fiziol. Zh. im. I. M. Sechenova, 84, No. 4, 385–390 (1998).Google Scholar
  8. 8.
    M. Cheido and G. Idova, “The different contributions of kappa and mu opioid receptors to immunomodulation: the roles of neurotransmitter systems,” Sib. Vestn. Psikhiatr. Narkol., 1, No. 27, 28–30 (2003).Google Scholar
  9. 9.
    M. A. Cheido, G. V. Idova, and L. V. Devoino, “Serotonin-dependent suppression of the immune response by kappa opiate receptors,” Byull. Éksperim. Biol. Med., 9, 291–292 (1993).Google Scholar
  10. 10.
    N. M. Barnes, and T. Sharp, “A review of central 5-HT1A receptors and their function,” Neuropharmacology, 38, 1083–1152 (1999).PubMedCrossRefGoogle Scholar
  11. 11.
    B. Berger, A. K. Rothmaier, F. Wedekind, J. Zentner, T. J. Feuerstein, and R. Jackisch, “Presynaptic opioid receptors on noradrenergic and serotoninergic neurons in the human as compared to the rat neocortex,” J. Pharmacol., 148, No. 6, 795–806 (2006).Google Scholar
  12. 12.
    M. Boranic, D. Pericic, M. Poljak-Blazi, V. Sverko, and T. Marotti, “Suppression of immune response in rats by stress and drugs interfering with metabolism of serotonin,” Ann. N.Y. Acad. Sci., 496, 485–491 (1987).PubMedCrossRefGoogle Scholar
  13. 13.
    W. Carlezon, C. Beguin, J. DiNieri, M. H. Baumann, M. Richards, M. Todtenkopf, R. B. Rothman, Z. Ma, D. Y. Lee, and B. M. Cohen, “Depressive-like effects of the kappa-opioid receptor agonist salvinorin A on behavior and neurochemistry in rats,” J. Pharmacol. Exptl. Ther., 316, No. 1, 440–447 (2006).CrossRefGoogle Scholar
  14. 14.
    Y. Cui, T. F. Lee, L. I. Kramarova, and L. C. Wang, “The modulatory effects of mu and kappa-opioid agonists on 5-HT release from hippocampal and hypothalamic slices of euthermic and hibernating ground squirrels,” Life Sci., 53, No. 2, 1957–1965 (1993).PubMedCrossRefGoogle Scholar
  15. 15.
    Y. Cui, T. Lee, and L. C. Wang, “Species difference in the modulatory effect of kappa agonist on 5-HT release from ground squirrel and rat hippocampus,” Neurosci. Lett., 175, No. 1–2, 126–128 (1994).PubMedCrossRefGoogle Scholar
  16. 16.
    A. J. Cunningham, “A method of increased sensitivity for detecting single antibody forming cells,” Nature, 207, 1106 (1995).CrossRefGoogle Scholar
  17. 17.
    G. C. Desjardins, J. R. Bramer, and A. Beandet, “Distribution of mu, delta- and kappa-opioid receptors in the hypothalamus of the rat,” Brain Res., 536, 114–123 (1990).PubMedCrossRefGoogle Scholar
  18. 18.
    L. V. Devoino and G. V. Idova, “Influence of some drugs on the immune response. IV. Effect of serotonin, 5-hydroxytryptophan, iproniazid and p-chlorphenilalanine on the synthesis of IgM and IgG antibodies,” Eur. J. Pharmacol., 22, 325–331 (1973).PubMedCrossRefGoogle Scholar
  19. 19.
    L. V. Devoino, G. V. Idova, E. L. Alperina, and M. A. Cheido, “Brain neuromediator systems in the immune response control: pharmacological analysis of pre- and postsynaptic mechanisms,” Brain Res., 633, 267–274 (1994).PubMedCrossRefGoogle Scholar
  20. 20.
    J. De Vry, R. Schreiber, C. Melon, M. Dalmus, and K. R. Jentzsch, “5-HT1A receptors are differentially involved in the anxiolytic- and antidepressant-like effects of 8-OH-DPAT and fluoxetine in the rat,” Eur. J. Neuropsychopharmacol., 14, No. 6, 487–495 (2004).CrossRefGoogle Scholar
  21. 21.
    A. Fletcher, E. A. Forster, D. J. Bill, et al., “Electrophysiological, biochemical, neurohormonal and behavioural studies with WAY-100635, a potent, selective and silent 5-HT1A receptor antagonist,” Behav. Brain Res., 73, 337–353 (1996).PubMedCrossRefGoogle Scholar
  22. 22.
    C. Gaveriaux-Ruff, F. Simonin, D. Filliol, and B. L. Kieffer, “Enhanced humoral response in kappa-opioid receptor knockout mice,” J. Neuroimmunol., 134, No. 1–2, 72–81 (2003).PubMedCrossRefGoogle Scholar
  23. 23.
    A. Gulati, P. Ramarao, and H. N. Bhargava, “Effect of repeated administration of U-50488H, a kappa-opioid receptor agonist, on central 5-HT1 and 5-HT2 receptors in the rat,” Pharmacology, 39, 145–153 (1989).PubMedCrossRefGoogle Scholar
  24. 24.
    J. Hennig, H. Becher, and P. Netker, “5-HT agonist-induced changes in peripheral immune cells in healthy volunteers: The impact of personality,” Behav. Brain Res., 73, 359–363 (1996).PubMedCrossRefGoogle Scholar
  25. 25.
    M. C. Hernandez, L. R. Flores, and B. M. Bayer, “Immunosuppression of k-opiate receptors,” J. Pharmacol. Exptl. Ther., 267, No. 3, 1336–1341 (1993).Google Scholar
  26. 26.
    B. Y. Ho and A. E. Takemori, “Release by U-50488H of [3H] serotonin from brain slices and spinal cord synaptosomes of U-50488-tolerant and nontolerant mice,” J. Pharmacol. Exptl. Ther., 254, 8–12 (1990).Google Scholar
  27. 27.
    B. D. Jankovic and J. Radulovic, “Quaternary naltrexone: its immunomodulatory activity and interaction with brain delta- and kappa-opioid receptors,” Immunopharmacology, 28, 105–112 (1994).PubMedCrossRefGoogle Scholar
  28. 28.
    J. Kamei, “Role of opioidergic and serotoninergic mechanisms in cough and antitussives,” Pulm. Pharmacol., 9, No. 5–6, 349–356 (1996).PubMedCrossRefGoogle Scholar
  29. 29.
    M. Kunihara, M. Ohyama, and M. Nakano, “Central monoaminergic mechanisms in mice and analgesic activity of spiradoline mesylate, a selective kappa-opioid receptor agonist,” Eur. J. Pharmacol., 214, No. 2–3, 111–118 (1992).PubMedCrossRefGoogle Scholar
  30. 30.
    R. R. Lanzenberger, M. Mitterhauser, C. Spindelegger, W. Wadsak, et al., “Reduced serotonin-1 A receptor binding in social anxiety disorder,” Biol. Psychiatry, 61, No. 9, 1081–1089 (2007).PubMedCrossRefGoogle Scholar
  31. 31.
    A. Mansour, S. Burke, R. J. Pavlic, H. Akil, and S. J. Watson, “Immunohistochemical localization of the cloned k1 receptor in the rat CNS and pituitary,” Neurosci., 71, No. 3, 671–690 (1996).CrossRefGoogle Scholar
  32. 32.
    S. Miyamoto, A. S. LaMantia, G. E. Duncan, P. Sullivan, J. H. Gilmore, and J. A. Lieberman, “Recent advances in the neurobiology of schizophrenia,” Mol. Interventions, 3, No. 1, 27–39 (2003).CrossRefGoogle Scholar
  33. 33.
    E. L. Morgan, “Regulation of human B lymphocyte activation by opioid peptide hormones. Inhibition of IgG production by opioid-receptor class (mu-, kappa-, and delta) selective agonists,” J. Neuroimmunol., 65, No. 1, 21–30 (1996).PubMedCrossRefGoogle Scholar
  34. 34.
    K. Nemmani, S. Gallapalli, and P. Ramarao, “Potentiation of kappaopioid receptor agonist-induced analgesia and hypothermia by fluoxetine,” Pharmacol. Biochem. Behav., 69, No. 1–2, 189–193 (2001).PubMedCrossRefGoogle Scholar
  35. 35.
    D. H. Overstreet, R. C. Commissaris, R. De La Garza II, et al., “Involvement of 5-HT1A receptors in animal tests of anxiety and depression: evidence from genetic models,” Stress, 6, No. 2, 101–110 (2003).PubMedCrossRefGoogle Scholar
  36. 36.
    T. C. Pellegrino, “Role of central 5-HT2 receptors in fluoxetineinduced decreases in T lymphocyte activity,” Brain Behav. Immun., 16, 87–103 (2002).PubMedCrossRefGoogle Scholar
  37. 37.
    K. R. Powell, M. J. Picker, and L. A. Dykstra, “Serotonin involvement in the discriminative stimulus effects of mu and kappa-opioids in rats,” Behav. Pharmacol., 5, 255–264 (1994).PubMedGoogle Scholar
  38. 38.
    A. Pfeiffer, B. Brantl, A. Herz, and H. M. Emrich, “Psychotomimesis mediated by k-opiate receptors,” Science, 233, 774–776 (1986).PubMedCrossRefGoogle Scholar
  39. 39.
    J. Radulovic and B. D. Jankovic, “Opposing activities of brain opioid receptors in the regulation of humoral and cell-mediated immune responses in the rat,” Brain Res., 661, No. 1–2, 189–195 (1994).PubMedCrossRefGoogle Scholar
  40. 40.
    J. Radulovic, C. Miljevic, D. Djergovic, V. Vujic, J. Antic, S. von Horsten, and B. D. Jankovic, “Opioid receptor-mediated suppression of humoral immune response in vivo and in vitro: involvement of kappa opioid receptors,” J. Neuroimmunol., 57, No. 1–2, 55–62 (1995).PubMedCrossRefGoogle Scholar
  41. 41.
    V. P. L. Reddy and H. N. Bhargava, “Abstinence from U-50488, a kappa-opiate receptor agonist, decreases the binding of [3H] DPAT to 5-HT1A receptors in the hypothalamus of the rat,” Neuropharmacology, 31, 1243–1249 (1992).PubMedCrossRefGoogle Scholar
  42. 42.
    R. Tao and S. B. Auerbach, “Mu-opioids disinhibit and kappa-opioids inhibit serotonin efflux in the dorsal raphe nucleus,” Brain Res., 1049, No. 1, 70–79 (2005)PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, Inc. 2009

Authors and Affiliations

  1. 1.State Research Institute of Physiology, Siberian BranchRussian Academy of Medical SciencesNovosibirskRussia

Personalised recommendations